Lupin has corrected by ~16% over the last one month due to worries on 483 (regulatory) observations by USFDA on Mandideep and Goa facilities and smaller-than-expected Glumetza pricing and revenues. Management has clarified that 483 observations on Mandideep are benign and unlikely to materially impact the business.